Logo small

Medical Rationale: Autoimmune diseases

MedExpress Team


Published April 4, 2023 16:01

Medical Rationale: Autoimmune diseases - Header image
- Autoimmune diseases have many faces and affect many areas of medicine. There is a lack of pathways for patients to navigate between them, especially from the PCP level. The urgent need is for early diagnosis, cooperation between specialists, the operation of reference centers and access to innovative therapies," recommended Prof. Brigid Kwiatkowska, national consultant in rheumatology, during the Meeting of the Expert Council on Autoimmune Diseases of the Medical Council of State on March 30.

The consequence of autoimmune diseases, in which the body's immune system destroys its own cells and tissues, is often progressive disability. They affect ca. 3.5% of the population, 75% of whom are women. According to the European Parliament report "Autoimmune Diseases - Modern Diseases," there has been a significant increase in the incidence of these diseases over the past decade.

Psoriasis and AD

Prof. Irena Walecka, consultant of the Mazovian province in dermatology and venereology, who heads the Dermatology Clinic of the PIM MSWiA in Warsaw, stressed that thanks to the changes introduced by the health department, the psoriasis treatment program is truly ideal. - We have 11 drugs, one new one included since March this year, the criterion for skin lesions has been lowered, which allows modern treatment of moderate psoriasis, instead of from the age of 6 we can treat children from the age of 4, the therapy is available for pregnant and breastfeeding women, there is the possibility of remote consultations. The treatment program is patient and doctor friendly," she concluded.

Prof. Witold Owczarek, head of the Department of Dermatology at WIM - PIB in Warsaw, spoke about the needs of patients suffering from atopic dermatitis (AD) - a chronic, recurrent and incurable dermatosis that occurs in both children and adults.

Currently, patients with severe forms of the disease have access to innovative therapy, while patients with moderate forms could also benefit clinically. The latest treatment option for AD is baricitinib. It is the first targeted synthetic drug in oral form. - The benefits of early treatment of the disease at a lower stage translate into an adequate, effective, long-lasting response to therapy, Prof. Witold Owczarek stressed.

Experts pointed out that for adults with severe AD, who experience itching and pain 24/7 and against whom all therapeutic options available in Poland, i.e. topical corticosteroids or calcineurin inhibitors, have proved...

Content locked

To gain access to the complete English section of the, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also